ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.161,01
1,32%
S&P 500
5.099,96
1,02%
Dow Jones
38.239,66
0,40%
Euro vs US Dollar
1,06965
0,00%
Bitcoin
63.487,92
0,12%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Arbutus Biopharma Corporation (ABUS)

  7. Arbutus Biopharma Corporation (ABUS) News

ABUS Arbutus Biopharma Corporation

2,73
0,01 (0,37%)
27 Apr 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Arbutus Biopharma Corporation ABUS NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
0,01 0,37% 2,73 06:00:00
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
2,73 2,70 2,78 2,73 2,72
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
18.4.202413:30GLOBEArbutus to Report First Quarter 2024 Financial Results and..
04.4.202414:30GLOBEArbutus Biopharma Announces Claim Construction Ruling in its..
08.3.202413:30GLOBEArbutus to Participate in Two Upcoming Investor Conferences
05.3.202422:48EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
29.2.202413:31EDGAR2Form 8-K - Current report
29.2.202413:30GLOBEArbutus Reports Fourth Quarter and Year End 2023 Financial..
15.2.202413:30GLOBEArbutus to Report Fourth Quarter and Year End 2023 Financial..
14.2.202422:38EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14.2.202416:48EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
06.2.202401:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.2.202401:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.2.202401:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.2.202401:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08.1.202413:31EDGAR2Form 8-K - Current report
08.1.202413:30GLOBEArbutus Announces 2024 Corporate Objectives and Provides..
04.1.202422:09EDGAR2Form 8-K - Current report
21.11.202314:00EDGAR2Form SC 13G - Statement of acquisition of beneficial..
09.11.202322:02EDGAR2Form 8-K - Current report
08.11.202313:30GLOBEArbutus to Present at Jefferies London Healthcare Conference
07.11.202322:18EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07.11.202313:31EDGAR2Form 8-K - Current report
07.11.202313:30GLOBEArbutus Reports Third Quarter 2023 Financial Results and..
07.11.202313:16EDGAR2Form 8-K - Current report
07.11.202313:15GLOBEArbutus Announces CEO, William Collier, to Retire December..
24.10.202313:30GLOBEArbutus to Report Third Quarter 2023 Financial Results and..
18.10.202313:30GLOBEArbutus to Present at H.C. Wainwright 4th Annual Hepatitis B..
11.10.202314:06EDGAR2Form 8-K - Current report
11.10.202314:05GLOBEArbutus Announces Multiple Abstracts Accepted for..
11.9.202323:07EDGAR2Form SC 13G - Statement of acquisition of beneficial..
11.9.202322:16EDGAR2Form 8-K - Current report
11.9.202322:15GLOBEArbutus Announces Pipeline Updates and Dosing of the First..
07.9.202313:30GLOBEArbutus to Participate in Two Upcoming Investor Conferences
03.8.202322:18EDGAR2Form S-8 - Securities to be offered to employees in employee..
03.8.202322:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03.8.202313:31EDGAR2Form 8-K - Current report
03.8.202313:30GLOBEArbutus Reports Second Quarter 2023 Financial Results..
20.7.202313:30GLOBEArbutus to Report Second Quarter 2023 Financial Results and..
13.7.202322:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13.7.202322:11EDGAR2Form 3 - Initial statement of beneficial ownership of..
12.7.202322:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12.7.202322:48EDGAR2Form 3 - Initial statement of beneficial ownership of..
12.7.202322:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12.7.202322:10EDGAR2Form 3 - Initial statement of beneficial ownership of..
12.7.202313:31EDGAR2Form 8-K - Current report
12.7.202313:30GLOBEArbutus Appoints Melissa V. Rewolinski, PhD to its Board of..
10.7.202322:02EDGAR2Form 8-K - Current report
10.7.202322:01GLOBEArbutus Appoints Two New Executives
21.6.202313:30GLOBEArbutus Doses First Patient in Additional Treatment Arm of..
21.6.202308:01GLOBEArbutus Presents Preliminary AB-729 and Pegylated Interferon..
07.6.202308:01GLOBEArbutus to Present AB-729 and AB-836 Data at EASL Congress..

Kürzlich von Ihnen besucht

NASDAQ
ABUS
Arbutus Biopharma
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten